High-Throughput
Mass Spec.
Unleashed.
High‑throughput mass spectrometry (HT‑MS) has evolved beyond simply increased sample speed — it is becoming the analytical backbone of biopharma R&D and operations. From discovery to development, quality monitoring, and beyond, every experiment generates large volumes of complex, multidimensional data. Managing terabytes of this data requires a purpose‑built digital ecosystem that can scale with you.
This is where Genedata comes in.
Genedata is invaluable for our ability to process the amount and especially the size of data files generated in HT-MS screening. I cannot quantify the improvement - either we were doing it with Genedata or not doing it at all.
With Genedata we can analyze, review data, and report results from ~ 500 samples in a process characterization study in less than one week, with one operator and one reviewer.
100-fold screening throughput increase [with Genedata] enables better quality of biologics, and faster time to clinic: up to 6 months. Another great benefit is to leverage ML for AI-based drug discovery.
Multiplexed MS.
Faster Discovery.
Intact Mass. Covalent Binding. Affinity Selection Mass Spectrometry (AS-MS). HT Peptide Mapping – and more. The Genedata Biopharma Platform covers all MS-based applications, enabling you to simplify data analysis, enhance quality assurance, and overcome bottlenecks. Learn how Pfizer and Genedata partnered in the development of a fast and robust HT-MS assay that accelerates covalent ligand discovery in biopharmaceutical R&D.
AI-driven Developability.
Better Candidates.
Integrate HT-MS workflows with your corporate data and leverage end-to-end automation to enable streamlined workflows and faster predictions. Discover how Sanofi is transforming drug discovery by integrating high-throughput chemical liability screening with Machine Learning/Artificial Intelligence (ML/AI) applications into its antibody development workflows. This innovative approach boosts throughput by up to 100-fold, enabling earlier identification of candidates with favorable developability profiles.
Decision-ready Data.
Biological-level Insights.
Import raw data from all major MS instruments and combine it with metadata from compound registration and other systems to automatically parameterize MS analysis for each sample in the screen. Out-of-the-box, Genedata offers data visualizations at multiple levels — assays, plates, wells, spectra, and compounds — enabling at a glance data interpretation and seamless integration of MS-based assays with industry-standard screening quality control and analysis practices. Fully automate HT-MS spectral processing, data analysis, quality control, and reporting, enabling you to focus on the biological impact of your work.
Comprehensive Development.
Deep Understanding.
With increasing demand for large-scale peptide mapping of therapeutic candidates, automating time-consuming manual processes is essential for achieving high-throughput, high-quality results. Learn how Janssen, now J&J Innovative Medicines, leverages Genedata to automate targeted MS-based peptide mapping of protein therapeutic samples, drive workflow processes using sample-specific metadata, and standardize reporting to enable meaningful data aggregation.
Unlocking Biopharma Discovery: Why
a Digital Ecosystem Matters for HT-MS
Strategies for Rapid Intact Mass Screening Analysis: Achieving One-Second per Well
A High-Throughput Mispairing Assay Using Intact Mass Spectrometry
Higher Throughput Peptide Mapping Workflows Enabled by Automation of MS Data Analysis, Review, and Reporting